▁Introduction 10.375
: 6.5234375
<0x0A> 3.994140625
In 4.58203125
▁the 1.7373046875
▁ever 8.140625
- 0.45654296875
ad 5.375
van 0.01983642578125
cing 0.0003712177276611328
▁field 2.42578125
▁of 0.012115478515625
▁cancer 6.5390625
▁research 1.0029296875
, 0.131103515625
▁British 10.109375
▁Bi 8.40625
ote 1.5322265625
ch 1.0078125
' 4.46484375
s 0.00649261474609375
▁revolution 5.19140625
ary 0.01593017578125
▁anti 4.21875
- 0.01739501953125
can 0.375
cer 0.0023860931396484375
▁treatment 2.572265625
▁Mar 9.859375
im 4.9921875
ast 2.203125
at 0.0145416259765625
▁has 1.291015625
▁gar 4.99609375
ner 5.7697296142578125e-05
ed 0.0005345344543457031
▁significant 2.66015625
▁attention 0.68798828125
▁and 2.314453125
▁now 5.09765625
▁stands 2.837890625
▁at 2.2421875
▁a 3.16796875
▁critical 2.439453125
▁jun 0.466796875
ct 1.9669532775878906e-05
ure 0.00012600421905517578
. 1.0771484375
▁As 3.037109375
▁anal 8.6015625
yst 0.0576171875
s 0.11334228515625
▁and 1.8154296875
▁exper 3.53125
ts 9.47713851928711e-05
▁eager 6.08984375
ly 0.02093505859375
▁anticip 2.048828125
ate 0.0042266845703125
▁the 0.5087890625
▁latest 4.77734375
▁develop 1.654296875
ments 0.0006885528564453125
▁at 5.65234375
▁the 0.96728515625
▁European 5.21484375
▁Society 3.7734375
▁for 0.51123046875
▁Medical 0.0859375
▁On 0.06207275390625
col 0.0003521442413330078
ogy 8.463859558105469e-06
▁( 0.93896484375
ES 0.0305938720703125
MO 0.0002503395080566406
) 0.10662841796875
▁meeting 2.59375
, 0.9541015625
▁all 5.578125
▁eyes 0.070068359375
▁are 0.43017578125
▁on 0.37548828125
▁the 0.8447265625
▁un 5.6484375
ve 2.95703125
iling 0.0110931396484375
▁of 0.0221710205078125
▁new 2.85546875
▁evidence 3.673828125
▁on 2.712890625
▁Mar 2.08203125
im 0.0022029876708984375
ast 0.00251007080078125
at 0.0024547576904296875
' 0.28662109375
s 0.0016241073608398438
▁effic 1.728515625
acy 8.296966552734375e-05
, 2.912109375
▁potential 5.109375
▁side 1.107421875
▁effects 0.133056640625
, 0.5732421875
▁and 0.1973876953125
▁its 3.3359375
▁promise 5.6796875
▁in 2.62109375
▁the 1.4130859375
▁battle 2.96875
▁against 0.0926513671875
▁cancer 1.052734375
. 0.163330078125
<0x0A> 0.3857421875
Background 7.6015625
: 1.1416015625
<0x0A> 9.671875
Mar 0.69384765625
im 0.00263214111328125
ast 0.001033782958984375
at 0.0005497932434082031
, 1.716796875
▁a 1.0810546875
▁ground 6.1796875
bre 0.429931640625
aking 0.00044608116149902344
▁drug 3.02734375
▁developed 1.6787109375
▁by 0.1644287109375
▁British 0.3291015625
▁Bi 0.03955078125
ote 0.00017893314361572266
ch 0.00957489013671875
, 0.412109375
▁has 1.38671875
▁shown 2.4296875
▁promise 2.064453125
▁in 0.2181396484375
▁in 5.484375
hib 0.1829833984375
iting 0.00323486328125
▁the 0.80126953125
▁growth 0.85595703125
▁of 0.1668701171875
▁cancer 1.044921875
ous 1.322265625
▁tum 0.8818359375
ors 0.340576171875
. 1.3642578125
▁By 4.64453125
▁target 1.9248046875
ing 0.0015201568603515625
▁Matrix 11.859375
▁Metal 0.1998291015625
lo 0.0016679763793945312
prote 0.0411376953125
in 0.06402587890625
ases 1.396484375
▁( 0.263427734375
M 0.066650390625
MP 0.00524139404296875
s 0.251953125
), 0.27294921875
▁en 7.88671875
zym 0.037506103515625
es 0.002155303955078125
▁that 0.52880859375
▁promote 3.4765625
▁cancer 1.3193359375
▁cell 0.94580078125
▁growth 0.288818359375
▁and 1.6318359375
▁met 1.326171875
ast 0.0126800537109375
asis 0.024749755859375
, 0.04510498046875
▁Mar 0.245849609375
im 0.0009455680847167969
ast 0.001659393310546875
at 0.0010814666748046875
▁a 4.32421875
ims 0.0643310546875
▁to 0.006443023681640625
▁dis 3.556640625
rupt 0.058868408203125
▁tum 1.798828125
or 0.051666259765625
▁pro 2.291015625
gression 0.17919921875
▁and 0.71630859375
▁potentially 3.478515625
▁improve 4.06640625
▁patient 1.97265625
▁out 0.35009765625
comes 0.009246826171875
. 0.088134765625
▁Initial 7.0078125
▁studies 1.98828125
▁have 0.7216796875
▁show 7.65625
c 0.26171875
ased 0.00010859966278076172
▁its 4.65625
▁potential 2.3359375
▁in 1.1015625
▁various 5.44921875
▁cancer 1.732421875
▁types 0.1890869140625
, 0.28564453125
▁including 0.41064453125
▁breast 1.484375
, 0.46630859375
▁li 3.92578125
ver 0.0010099411010742188
, 0.055908203125
▁and 0.82421875
▁pro 1.9111328125
state 0.0017719268798828125
▁cancer 1.0966796875
. 0.377197265625
<0x0A> 0.6494140625
ES 4.80078125
MO 0.01064300537109375
▁Me 3.3984375
eting 0.0286865234375
: 0.5673828125
▁An 7.66796875
▁O 3.228515625
pport 0.0211944580078125
unity 0.11798095703125
▁for 0.8330078125
▁Break 3.818359375
through 0.004425048828125
s 1.548828125
: 2.66796875
<0x0A> 0.09527587890625
The 1.3037109375
▁eager 7.61328125
ly 0.400146484375
▁anticip 0.431640625
ated 0.0034961700439453125
▁ES 0.92578125
MO 0.0008487701416015625
▁meeting 0.428466796875
, 1.8017578125
▁one 5.63671875
▁of 0.005077362060546875
▁the 0.040313720703125
▁most 1.916015625
▁prominent 2.970703125
▁global 3.26953125
▁con 1.0576171875
ferences 0.053741455078125
▁on 2.51953125
▁cancer 1.080078125
▁research 0.388427734375
▁and 1.564453125
▁ther 4.37109375
ap 1.6279296875
ies 0.0008778572082519531
, 0.0166015625
▁presents 5.0
▁a 0.87255859375
▁valuable 4.6484375
▁platform 1.48828125
▁for 0.0897216796875
▁British 1.76953125
▁Bi 0.002452850341796875
ote 5.0187110900878906e-05
ch 0.001995086669921875
▁to 0.3837890625
▁show 0.8662109375
case 0.01163482666015625
▁the 1.658203125
▁latest 1.5634765625
▁evidence 2.115234375
▁on 0.364990234375
▁Mar 0.484130859375
im 0.0003516674041748047
ast 0.0013837814331054688
at 0.0008497238159179688
. 2.02734375
▁Research 6.046875
ers 0.106689453125
, 1.8017578125
▁on 2.427734375
colog 0.02679443359375
ists 0.00251007080078125
, 0.032745361328125
▁and 0.136962890625
▁anal 4.6328125
yst 4.506111145019531e-05
s 0.00026535987854003906
▁are 2.16796875
▁looking 4.28125
▁forward 0.27734375
▁to 0.003482818603515625
▁gain 4.0390625
ing 0.0833740234375
▁ins 2.4296875
ights 0.0026912689208984375
▁into 0.306884765625
▁the 0.388916015625
▁drug 2.134765625
' 0.02728271484375
s 0.0007343292236328125
▁progress 6.578125
▁in 2.142578125
▁clin 0.97265625
ical 0.00177001953125
▁tri 0.08740234375
als 2.2649765014648438e-06
, 1.37109375
▁further 5.859375
▁patient 8.4453125
▁response 6.0078125
▁data 2.79296875
, 0.072998046875
▁and 0.0767822265625
▁potential 1.4794921875
▁ref 11.625
in 0.00777435302734375
ements 0.10638427734375
▁that 3.384765625
▁may 1.3740234375
▁improve 1.271484375
▁its 0.9765625
▁effect 2.93359375
iveness 0.002597808837890625
. 0.462890625
<0x0A> 0.39208984375
E 4.60546875
ffic 2.76953125
acy 0.01593017578125
▁and 1.697265625
▁Saf 1.50390625
ety 5.5670738220214844e-05
: 0.410888671875
▁Key 7.828125
▁F 4.3203125
ocus 0.018798828125
▁Are 1.970703125
as 0.0003719329833984375
: 0.427490234375
<0x0A> 0.00212860107421875
Anal 4.92578125
yst 0.00687408447265625
s 0.01097869873046875
▁will 2.595703125
▁closely 2.462890625
▁examine 1.703125
▁the 0.74169921875
▁effic 0.7685546875
acy 1.71661376953125e-05
▁of 2.212890625
▁Mar 0.0830078125
im 0.00026726722717285156
ast 0.0013113021850585938
at 0.0003867149353027344
, 2.208984375
▁seeking 6.82421875
▁evidence 2.986328125
▁on 2.125
▁its 0.58251953125
▁ability 1.4716796875
▁to 0.003551483154296875
▁in 1.0625
hib 0.0008549690246582031
it 0.0005745887756347656
▁M 3.28515625
MP 0.00426483154296875
s 0.83349609375
▁effectively 6.84765625
. 2.58203125
▁D 6.265625
etailed 1.7421875
▁results 3.810546875
▁from 0.568359375
▁pre 3.236328125
cl 0.401123046875
in 1.430511474609375e-05
ical 0.00030112266540527344
▁and 1.5634765625
▁early 2.927734375
- 1.20703125
stage 0.7314453125
▁clin 0.4013671875
ical 0.0002613067626953125
▁tri 0.390380859375
als 9.059906005859375e-06
▁will 0.67724609375
▁provide 3.453125
▁a 2.8359375
▁vital 5.1640625
▁understanding 1.984375
▁of 0.11517333984375
▁the 1.0615234375
▁drug 0.5048828125
' 0.013214111328125
s 0.0004246234893798828
▁impact 3.712890625
▁on 0.170654296875
▁tum 1.228515625
or 0.11517333984375
▁growth 0.439697265625
, 2.044921875
▁pro 3.826171875
gression 0.129638671875
, 0.032470703125
▁and 0.0601806640625
▁disease 5.71875
- 1.609375
free 1.8603515625
▁surv 0.048065185546875
ival 0.0010271072387695312
▁rates 1.8310546875
▁in 2.287109375
▁different 3.037109375
▁cancer 0.5009765625
▁types 0.054473876953125
. 0.07891845703125
▁Moreover 4.9765625
, 0.0005393028259277344
▁with 5.41796875
▁safety 5.1171875
▁being 2.353515625
▁a 0.576171875
▁significant 3.98046875
▁concern 0.396240234375
, 2.26953125
▁anal 2.146484375
yst 0.0007567405700683594
s 0.0010080337524414062
▁will 0.0723876953125
▁scr 2.3671875
ut 4.601478576660156e-05
in 6.413459777832031e-05
ize 0.006748199462890625
▁any 2.982421875
▁evidence 4.35546875
▁of 0.92333984375
▁ad 2.005859375
verse 5.364418029785156e-06
▁side 2.4921875
▁effects 0.008026123046875
▁associated 2.48046875
▁with 0.0022735595703125
▁Mar 0.5634765625
im 0.0005617141723632812
ast 0.0017566680908203125
at 0.0012035369873046875
▁usage 2.94140625
. 0.341796875
<0x0A> 0.247802734375
P 4.40625
ot 0.0255279541015625
ential 0.0038394927978515625
▁Market 7.83984375
▁Imp 1.87109375
act 0.146240234375
: 0.0872802734375
<0x0A> 0.63134765625
The 2.009765625
▁impact 4.10546875
▁of 0.10986328125
▁Mar 0.307861328125
im 0.00022923946380615234
ast 0.0014200210571289062
at 0.0005116462707519531
▁on 0.57470703125
▁the 0.42431640625
▁ph 4.4765625
arma 0.0003867149353027344
ce 0.03271484375
ut 2.7418136596679688e-06
ical 3.3974647521972656e-05
▁market 1.3203125
▁could 2.76171875
▁be 0.1505126953125
▁substantial 2.642578125
, 1.09375
▁given 2.021484375
▁its 0.3779296875
▁potential 1.6396484375
▁as 2.6328125
▁a 0.354248046875
▁novel 3.203125
▁treatment 1.322265625
▁option 0.96240234375
. 2.755859375
▁Anal 3.6953125
yst 0.0013942718505859375
s 0.0025920867919921875
▁are 1.9462890625
▁particularly 3.810546875
▁interested 0.440185546875
▁in 0.023345947265625
▁its 2.73046875
▁compet 6.98828125
itive 0.10894775390625
▁advantages 1.060546875
▁over 1.2705078125
▁existing 1.28515625
▁treatment 3.3984375
▁modal 4.5625
ities 2.4080276489257812e-05
▁and 1.7890625
▁the 1.6552734375
▁potential 1.08984375
▁market 3.529296875
▁position 6.671875
ing 1.185546875
▁of 0.892578125
▁the 1.44921875
▁drug 0.28857421875
. 1.9755859375
▁Additionally 2.994140625
, 0.0007696151733398438
▁they 2.56640625
▁await 8.5
▁ins 4.046875
ights 0.000247955322265625
▁into 0.457763671875
▁the 1.2138671875
▁drug 1.5
' 0.00396728515625
s 0.00026702880859375
▁manufact 5.265625
uring 0.0318603515625
▁scal 7.109375
ability 0.0005869865417480469
▁and 0.59228515625
▁pr 4.28515625
icing 0.0011119842529296875
▁strateg 2.63671875
ies 0.0004622936248779297
, 1.2666015625
▁which 1.2958984375
▁could 0.60693359375
▁influence 3.345703125
▁its 1.0517578125
▁avail 4.51171875
ability 0.0003917217254638672
▁and 0.66650390625
▁access 1.4169921875
ibility 0.009124755859375
▁to 1.5908203125
▁patients 0.472412109375
▁across 2.77734375
▁the 0.416748046875
▁glo 0.2724609375
be 3.039836883544922e-05
. 0.0217742919921875
<0x0A> 0.051025390625
Imp 4.71484375
lications 1.3125
▁for 0.50341796875
▁Can 5.1640625
cer 0.002620697021484375
▁Pat 2.212890625
ients 0.0258636474609375
: 0.1624755859375
<0x0A> 0.058013916015625
Mar 1.7724609375
im 0.00033593177795410156
ast 0.0009965896606445312
at 0.00040149688720703125
' 1.4814453125
s 0.0012197494506835938
▁effic 2.46484375
acy 8.344650268554688e-06
▁in 1.9951171875
▁in 1.767578125
hib 0.0009489059448242188
iting 0.000736236572265625
▁M 0.63818359375
MP 0.0015411376953125
s 0.11810302734375
▁not 7.03515625
▁only 0.03533935546875
▁provides 2.5546875
▁hope 0.56103515625
▁for 0.2369384765625
▁patients 1.0302734375
▁currently 5.34765625
▁batt 2.365234375
ling 0.00022614002227783203
▁cancer 0.315673828125
▁but 1.1220703125
▁could 2.302734375
▁potentially 2.296875
▁offer 2.671875
▁an 2.98046875
▁alternative 0.7275390625
▁to 1.302734375
▁invas 5.4140625
ive 0.0019311904907226562
▁and 1.962890625
▁ag 4.40234375
gress 0.011322021484375
ive 0.0005750656127929688
▁treatment 1.375
▁approaches 2.759765625
. 0.4267578125
▁Depending 7.5234375
▁on 0.01214599609375
▁the 0.64697265625
▁evidence 6.1640625
▁presented 1.5830078125
▁at 0.36767578125
▁the 0.4658203125
▁ES 0.22509765625
MO 0.0002357959747314453
▁meeting 0.202880859375
, 0.05914306640625
▁Mar 3.126953125
im 0.00021946430206298828
ast 0.0008101463317871094
at 0.0003120899200439453
▁may 1.4677734375
▁p 5.81640625
ave 0.0018548965454101562
▁the 0.02728271484375
▁way 0.0113677978515625
▁for 0.2032470703125
▁personal 5.41015625
ized 0.00911712646484375
▁cancer 1.30859375
▁ther 1.3671875
ap 0.31396484375
ies 7.152557373046875e-06
▁that 1.1005859375
▁target 1.7509765625
▁individual 2.751953125
▁cancer 2.365234375
▁types 1.78125
▁more 4.69921875
▁precisely 2.423828125
, 1.8984375
▁potentially 1.693359375
▁transform 6.63671875
ing 0.0010461807250976562
▁the 0.81298828125
▁landscape 2.4453125
▁of 0.11968994140625
▁cancer 0.4072265625
▁treatment 0.57470703125
. 0.61083984375
<0x0A> 0.2349853515625
Con 4.703125
clusion 0.5009765625
: 0.04425048828125
<0x0A> 2.400390625
The 1.625
▁release 6.125
▁of 0.01666259765625
▁new 0.66162109375
▁evidence 0.381103515625
▁on 0.58837890625
▁Mar 0.211669921875
im 0.0001970529556274414
ast 0.0009870529174804688
at 0.0004143714904785156
▁at 2.16796875
▁the 0.208251953125
▁forth 4.7265625
coming 0.00018537044525146484
▁ES 0.0572509765625
MO 0.0004482269287109375
▁meeting 0.1356201171875
▁has 3.419921875
▁spark 4.40625
ed 0.00012636184692382812
▁immense 4.3515625
▁anticip 2.140625
ation 0.0008025169372558594
▁among 0.78662109375
▁on 0.94873046875
col 2.15625
ogy 4.1961669921875e-05
▁exper 0.86865234375
ts 1.5497207641601562e-06
, 1.4833984375
▁anal 2.4765625
yst 2.09808349609375e-05
s 0.00012552738189697266
, 0.00946807861328125
▁and 0.0782470703125
▁patients 0.91064453125
▁al 0.732421875
ike 6.556510925292969e-06
. 0.0726318359375
▁This 3.453125
▁ground 3.119140625
bre 0.0533447265625
aking 0.00010061264038085938
▁drug 1.0009765625
▁developed 5.8046875
▁by 0.00693511962890625
▁British 0.0233154296875
▁Bi 0.0026607513427734375
ote 2.2292137145996094e-05
ch 0.0019350051879882812
▁has 1.51953125
▁the 1.1806640625
▁potential 0.028167724609375
▁to 0.006511688232421875
▁revolution 1.517578125
ize 0.00225830078125
▁cancer 0.72509765625
▁treatment 0.2467041015625
▁by 2.072265625
▁in 0.495849609375
hib 9.85860824584961e-05
iting 0.00016427040100097656
▁tum 2.771484375
or 0.0197601318359375
▁growth 0.373046875
▁effectively 6.07421875
. 1.54296875
▁As 2.51171875
▁the 1.2734375
▁world 3.78515625
▁a 1.572265625
wa 0.0002646446228027344
its 1.1920928955078125e-06
▁the 1.0361328125
▁latest 0.4384765625
▁data 2.947265625
, 1.509765625
▁the 2.431640625
▁results 5.890625
▁may 4.65625
▁p 4.2265625
ave 0.0007119178771972656
▁the 0.004253387451171875
▁way 0.00768280029296875
▁for 0.06817626953125
▁a 1.96484375
▁new 0.86767578125
▁era 0.57763671875
▁of 0.48583984375
▁personal 0.59326171875
ized 0.0022125244140625
▁cancer 0.36279296875
▁ther 0.477294921875
ap 0.10186767578125
ies 3.5762786865234375e-06
▁and 2.3671875
▁offer 2.90625
▁renew 7.13671875
ed 0.0002467632293701172
▁hope 0.01477813720703125
▁to 0.80615234375
▁millions 4.66015625
▁of 0.435791015625
▁patients 0.587890625
▁batt 2.728515625
ling 0.0002727508544921875
▁this 2.169921875
▁dead 1.51171875
ly 0.0007166862487792969
▁disease 0.034942626953125
. 0.048797607421875
